All In Biotech

Drug Trial Radar · NCT07471373

Pesticides and Infertility: Oxidative Stress Via Circulating Cell-free DNA and Gut/Genital Microbiome Signatures in Women With Endometriosis

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Feb 27, 2026

Primary completion

Feb 2028

Study completion May 2028

Sponsor

Lead sponsor
Centre Hospitalier Universitaire, AmiensAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Screening
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 43 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This project PestiEndoMicro aims to provide an innovative approach, studying endometriosis under the genital and gut microbiota scope. To realize this project, the investigators are planning to dose cfDNA to assess the oxidative stress caused by endometriosis and study its epigenetics. At the same time, the investigators will take a pragmatic approach by assessing pesticide exposure in these patients and estimate the correlation between gut or genital dysbiosis and chemical agent exposure. Also, the investigators will take the initiative to use classic culture, qPCR techniques, and NGS to establish signatures in vaginal, endometrial and gut microbiota in patients with endometriosis. With these approaches, the goal is to gain more knowledge about endometriosis and optimize early diagnosis by establishing a signature in the genital and gut microbiota, but also by dosing the cfDNA. By doing so the investigators could open new opportunities to develop new therapeutic strategies for endometriosis.

Conditions

  • Endometriosis
  • Infertility
  • Female Fertility
  • Cell Free DNA
  • Genital Microbiota
  • Vaginal Microbiota
  • Endometrial Microbiota
  • Pesticides
  • Gut Microbiota
  • Epigenetics

Interventions

  • Circulating DNA analysisBiological

    Circulating DNA analysis : For this study, 2 supernumerary EDTA tubes (10mL) of blood samples will be taken as part of the infectious workup.

  • Vaginal microbiota analysisBiological

    Vaginal microbiota analysis : In the study, a supernumerary vaginal sample from an endocervical smear will be taken as part of the biological workup.

  • Endometrial microbiota analysisBiological

    Endometrial microbiota analysis : As part of the study, an endometrial sample from a uterine rinse will be required. This flushing is a medical procedure performed outside the standard infertility or MAP management procedure and will only be carried out by a gynecologist once the patient has been included in the study and written consent has been received from the patient.

  • Intestinal microbiota analysisBiological

    Intestinal microbiota analysis (secondary objective): As part of the study, a fecal sample from a patient will be required. This donation is a voluntary act on the part of the patient, outside the standard procedure for infertility treatment or MAP, and will be requested after the patient has been informed of the purpose of the procedure. Once the SHIME has been inoculated, patient donation will be no longer necessary and won't be requested from subsequent patients.

  • Exposure to endocrine disruptors analysisBiological

    Exposure to endocrine disruptors analysis (secondary objective): The patient will be asked to donate a hair sample. This donation is a non-medical act performed outside the standard procedure for infertility management or MAP. In addition to hair sampling, a questionnaire on household characteristics, environment and possible exposure to endocrine disruptors will be given

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. quantification of circulating free DNA (cfDNA) between both groupsTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHRU Amiens

    Salouël, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.